Finoriq research workspace
AbbVie Inc. (ABBV) SEC Filings & Filing Highlights
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development. Review ABBV SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
- Company
- AbbVie Inc. (ABBV)
- Ticker
- ABBV
- Market Cap
- $446.9B
- Latest Price
- $252.93
- Industry
- Biotech & Pharma
AbbVie Inc. (ABBV) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for AbbVie Inc. (ABBV).
| Event | Form | Date |
|---|---|---|
| AbbVie held its 2026 Annual Meeting of Stockholders on May 8, 2026. The following is a summary...AbbVie held its 2026 Annual Meeting of Stockholders on May 8, 2026. The following is a summary of the matters voted on at that meeting | 8-K5.07 | 2026-05-12 |
| AbbVie Reports First-Quarter 2026 Financial ResultsAbbVie Reports First-Quarter 2026 Financial Results | 8-K2.02 | 2026-04-29 |
| Guidance Including the Impact of Acquired IPR&D and Milestones ExpenseGuidance Including the Impact of Acquired IPR&D and Milestones Expense | 8-K2.02 | 2026-04-03 |
| AbbVie Inc.: Corporate updateOn March 4, 2026, AbbVie Inc. (“AbbVie”) completed its previously announced underwritten public offering (the “Notes Offering”) of $750,000... | 8-K8.01 | 2026-03-04 |
| AbbVie Inc.: Corporate updateOn February 24, 2026, AbbVie Inc. (“AbbVie”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securit... | 8-K8.01 | 2026-02-26 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.